Jun 272013
 

PERAMPANEL

New data provides additional evidence for use of Fycompa in partial-onset epilepsy

HATFIELD, England, June 26, 2013 /CNW/ – New data from 11 abstracts, including two oral presentations, presented at the 30th International Epilepsy Congress (IEC) in Montreal, Canada provide additional data on the safety, efficacy and impact on quality of life (QOL) of once daily Fycompa® (perampanel) as adjunct treatment in partial-onset epilepsy, the most common form of seizures.

http://www.newswire.ca/en/story/1190177/new-fycompa-perampanel-data-presented-at-international-epilepsy-congress-iec

 

Perampanel (trade name Fycompa) is an antiepileptic drug developed byEisai Co. that acts as a selective noncompetitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors.

Perampanel was found to be effective in the treatment of refractory partial-onset seizures in three pivotal (Phase 3) clinical trials and has been approved for marketing under the brand name Fycompa by the European Medicines Agency. The minimum effective dose is 4 mg once daily; doses of 8 mg and 12 mg daily provide a greater therapeutic benefit with a corresponding increase in adverse events. Dizziness and somnolence/sedation/fatigue are the most frequent dose-related adverse events. The drug is currently approved, for the control of partial-onset seizures, in those of both sexes who suffer from epilepsy and who are 12 years of age and older, by the Food and Drug Administration, and is considered to be a scheduled drug (an agent with the potential for addiction). Perampanel has been studied in other clinical indications includingParkinson’s disease.

Share

 Leave a Reply

(required)

(required)


one + 5 =

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: